Thank you, Fred.
which have We've challenges, the ongoing good also discuss customer we order XXXX, moment. is a territory indicator a strong which sales demand. volumes and will and into Moving addressing been February, seen of January in shipping I in
the now as forward, place commercial much of Looking a which of sales grow strategic forming well our is off optimistic five resources, comprised includes accounts. data of success primary industry corporate will plan in our council, our for we One, addition platforms, and This analytic is stronger tools XXXX and infrastructure Biofrontera five positioned an for inside are strong we developing and the KOLs for across rollout upon a various foundation advisory business. and kick of larger reasons. function, we
utilized by convenience Two, cryotherapy been past levels. and due reimbursement historically has to dermatologists broadly
recent in as treatment. and single and therapy, field However, further opposed therapy support guidelines legion should reimbursement of treatment sales this to PDT shifts favor directed
our of year better and their patient in drive treatment treatment plans. will continue initiatives education Three; of while Four, benefits our customers following educated also and medical paths affairs PDT with on and providing the should increasingly as treatment into to the becoming we about comprehensive real strengthened are of our incorporate which encourage our AK our help a field Ameluz's to of more therapy, use PDT a marketing recognition care physicians continuum approach XXXX, This management. world efforts, focus will support demand. accomplishments disease
investing And sales five, are growth force. Fred our lever, mentioned, in our we as key
poised for new these beyond. manager. account, plan force of the growth expand fact, XXXX Taking into in to reps comprised regional year In of another we sales by team we believe are adding this factors eight a regional and we all and solid sales
our XXXX sales many growth. to were in There in highlights addition
increased the engagement well product analyst medical live marketing Through as our product campaign and opinion webinars our scientific conferences, as elevated awards. foundations, On partner medical front, department Biofrontera and disease demonstrations. medical industry through won as awareness and medical with leaders trusted a affairs at website education and key several
We help we providing in These disease great podcasts CME and dermatologists. CME strategy individualizing content participation into and programs a on videos, grants progression, were move by myths, furthered emails. non-CME and a educational our gaining as our treatment, from XXXX. web success medical significant these initiatives dispelling With for and traffic of focusing variety support
research, of treatment PDT in conference therapy, keratosis. approaches sessions discussing reviewed data of treatment the from the showcased on initiated photodynamic peer after as well a new two investigator PDT concepts field four to highlighting increase analysis We advancement we treatment for AK an saw world pharmacoeconomics of publications significant therapy and especially actinic alternative, a the and as posters real as directed
XXXX expansion growing with focused portfolio therapies. coupled and we of community on our commercializing growth. should medical a company position in and to and us dermatology momentum our as products for dermatological This the help Biofrontera initiatives support is
marketing therapy $X a billion are a to a commercial best-in-class We business market.
our by success customers be and to driven to Our customers. current new sell more ability gain will products
customer goal investing direction. groups of and by our described many to cultivating efforts wide year, markets to that council. engaging larger we inside support these the commercial XXXX and KOL over with including corporate approach and space, pivotal to in medical commercial This have and education a sales key industry enable the management was the and and capabilities, expertise, and cover adding activities development the affairs across broadening the ramping was opinion infrastructure marketing adding To of a customer multi-pronged end, strategy last and and a and account accounts, this business of support in work key advisory leaders influential expanding key
much XXXX. investing lifting in these done, business the of in the heavy completed never is While we in areas
is and ongoing force. optimization sales area our investment of One
finished We XXXX to During XX% number COVID, and this force we pre-COVID. had of significantly our the sales with had sales we dermatologists. headcount relationships and territories reduce impacted of with
the solid and commercial of and grow the investments in sales in not still materially gains. parts did growth necessary market achieved share Given other the infrastructure, XXXX we force
we law results. total, basically, We've a an small QX in performance relatively that reps However, outsized have saw a on the variances impact few the this a where variability meaningful challenge with experienced is lean this can had impact team on in have quarterly by numbers. unexpected the of the
have in rep than productivity XXXX. their has per XXXX the fewer sales higher currently much We're XX% sales approximately proud resulted revenues are in record we in and our in now, roughly While evidenced than XXXX higher revenue that XX% and higher as quality our being XXXX. average by in reps, training
sales reach the In cash-flow footprint rep, XXXX, We sales sales around that our about on We per timing $X.X million $XXX,XXX of $X.X scope a expansion. in with to with per depending sales rep. in we positive can force. and scale generated full million project
our is step sales revenue significant before supportive two this newly of well existing our important understand anticipated any within utilization expansion. of is sales and force and It further With milestone departments, that to planned expansion, our label is our an tools increased occur maturation implemented to this grasp.
major for force, been team, have year. not which only this sales adding already The lever growth but we to current the is growing moving optimizing the forward
have our a a additional sales productive of provide coverage new will and expansion feet the reps only frequency are rep by more within region team their to more will reach that territories, street drive and pleased We will eight each an in XXXX. them will include overall. adding and on sales help announce to better but Not and manager growth, this make regional better
grow to with but reps grow has years, plan force, XX reps given the next to Our the sales revenue over we been quickly. to sales to between more XX force a we evaluating leverage potential larger sales the are could two the sales achieve
members in to of a looking ramp to meeting new with forward begin and the have as them up. of the weeks, in Woburn will sales We headquarters they all to team I'm coming few
We that for XXXX. team are very together putting excited we about the are
market driving and a Our actinic billion competitive treatment the treatments. excessive With specifically and therapeutic a is of for commercial our $XXX The few infrastructure treatments. portfolio field, greater current lesions of segment and key for lesions. of cryo supporting and our to $X the is expected AK target for AKs the keratosis therapies comprised treatments market of XX treatments future under than single billing office is the current PDT strategy, code across with million
grow competitive business a areas has These as patient of and underserved we that market premise high basic would advantage the focus A of been clinical and within treatment proportion provide treatments a reimbursement. strong further by population value an efficacy AK PDT. of field-based two favorable share a we as we as to due would with over represent where PDT value our well therapies that economic strategy gain providing
our than to market, the are played and XX% about dynamics we broadly within XX% market. pleased cryo market. the that According XXXX. not X.X% data, these expanding In which PDT of to across more target by treatments of We out see are grew PDT of PDT represent includes expected we the but about market, market we XX to utilization reason more the as lesions, only space, evidencing growing in
coverage not potential. targets It in for revenue market next grow. growth believe simply hit the or Any are We of indications of sales and expansions to upside strong new sources our Ameluz's with the to education have better required a label and current we order continued represent requires runway PDT. future couple label for years
XL. sources potential, and upside opportunities I'd products, RhodoLED cover additional with On like the starting label some to on expansion of updates
lesion face been is and XL diligently severity combination Ameluz R&D moderate Our field market, with to to partners to approved have lamp RhodoLED of business and working AKs FDA for the the manufacturing in mild and bring directed of treatments indicated scalp. an which and on directed
Unfortunately, the have supply to generation complexities challenges than impeded contains of efforts. lamp chain and our temporarily XXXX our related that more manufacturing lingering components next
our timing about commitment the speak can't as bring I I dermatologists at as the While juncture, to specifically RhodoLED this and to patients reiterate XL soon can possible.
leasing with surface areas source various Ameluz accessible treatment we our BF-RhodoLED remains to for available PD In and and current dermatologists sizes the light for meantime, through red encourage of treating of the financing, sales options, utilize AK.
enable we on therapies Durham As This portfolio we've of stated past our have calls, our the will industry are looking to treatments. serving while base better commercial customers and expanding expand to built we leverage of us infrastructure and relationships
enrolled to and trial would AG, The development extremities, Biofrontera progressing label multi-center in treatment. are per clinical existing expansion and safety few the further BF-RhodoLED Phase expand This our market along we per our treatment investigating months. our the in this of positioning is completion open change. tube next licenseor lamp competitive three I significant opportunities. our use of with We provide in with treatment trials is that anticipated label advantage a include label conducting once able neck phase of the trunk are the to Ameluz multiple an label tubes will over XX%
Phase the The centers. seven chunk Phase in the clinical enrolled study two the enrolment. the that using here three Upon accelerate extremities, completion expect at of study has X X now study we patients of sites tubes, recently and will neck addition launched safety
over cell in moderate carcinoma Phase CX trial contractually expand trial superficial multicenter is of double-blind include Phase could additional moderate severe carcinoma carcinoma, Beyond basal squamous portfolio for The our II cell acne the is III and enrolled studies treatment, in AK XX% that severe the Ameluz's there and committed randomized and and superficial to PDT progress basal expansion are acne. XX% cell to about enrolled. to
$X serve All projects the beyond strengthen we market clinical of further development the today. access market longer well will open these dermatology existing to term and our profile billion
portfolio conditions continuum additional dermatologists along as of treatment priority evaluate PDT, for As areas we our with and well that expansion AK interests for are post of treat. additional the as opportunities therapy diagnosis,
Another minor medicine a of bacterial treatment revenue source the impetigo, of Depi, topical skin for approved prescription a is infection.
process commercial with and this the for on licenser our setting on up are XXXX. We at time are contract a manufacturer impact of working pace new by
We to value, are exploring shareholder other opportunities, this maximize options update additional commercial to also hope you we licensing including on and which year.
We growth were first Overall, full year We invested company. raised pivotal XXXX rigor a we was our publicly a by clinical in support that recorded our strategy, and public we completed the our to accomplishments, in XX% record We established recognized life. our increased force industry infrastructure traded succeeded high, Biofrontera. the our of for fund increase target to cash and we successfully company large as marketing our any market, in and revenues we by to pre-COVID for footprint. without eclipsed share this our and attractive peers and our year sales
We XXXX exciting are to to an accelerating year looking a and forward are start with far so in off great growth.
by grow cryotherapy. expansion, expect as therapies XXXX, we sales rep improving sales Specifically, competitive revenues adverse to and driven PDT such least both share versus our factors gains by XX% productivity, force and at over continued
said expansion, to will We so. to To sacrifice earlier, our our ways that evaluating momentum are in the committed do cost we do shareholders opportunistic we are growth underway strategy be to reinvigorating not bringing control in sales and opportunities pricing reiterate continue already and to our what anticipate. value Fred finding
Tony now Thank you turn Q&A. to I the to for will over call time. the your moderate
